Clinical trial · Observational
European Multicentric Study on Parathyroid Carcinoma
NCT05789680CI-TRIAL-00065107EMS-PCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main aim of the study is to evaluate the incidence of post-operative diagnosis of PC and atypical parathyroid neoplasm in patients who underwent surgery for pHPT in different European centers using the EUROCRINE® database. Moreover, we aim to evaluate the peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in these patients category.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Parathyroid Carcinoma | Parathyroid Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgical treatment of parathyroid carcinoma | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Parathyroid carcinoma among patients undergoing surgical treatment of primary hyperparathyroidism
- description
- All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for primary hyperparathyroidism and received histopathologic diagnosis of parathyroid carcinoma from 2015 till 2021 will be included
- interventionNames
- Procedure: Surgical treatment of parathyroid carcinoma
Primary outcomes (1)
- measure
- Incidence of parathyroid carcinoma
- timeFrame
- January 2015-January 2021
- description
- Descriptive analysis of the exact incidence of parathyroid carcinoma among patients undergoing surgical treatment of primary hyperparathyroidism in European centers.
Secondary outcomes (1)
- measure
- Oncologic outcome
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: All adult (18 years old and older) patients that underwent surgery for primary hyperparathyroidism with a final histology of parathyroid carcinoma from 2015 till 2021. Inclusion Criteria: * All adult (18 years old and older) patients * underwent surgery * final histology of parathyroid carcinoma * among European centers that participate in the Eurocrine® database between 2015 and 2021 Exclusion Criteria: • Patients \<18 years old
References
Publications (0)
Data not yet available
No reference posted for this study.